The demand for radioligand therapy in Italy is increasing, due to the growing incidence of gastroenteropancreatic neuroendocrine tumors and recent regulatory changes allowing outpatient treatments.

Significant regional disparities in access to radioligand therapy were observed, with only three regions accounting for over 85% of hospital discharges, while ten regions reported no treatments.

Defining a dedicated Diagnosis-Related Group code for nuclear medicine procedures is essential to ensure accurate resource allocation and equity in access to innovative treatments, such as radioligand therapy.